Table 2.
Characteristics of patients with Kaposi sarcoma who were lost to follow-up in four countries in sub-Saharan Africa (N1a + D2 in Fig. 1)
| AMPATH - Kenya N = 233 | ISS - Uganda N = 79 | Lighthouse - Malawi N = 74 | UATH & NHA - Nigeria N = 36 | Overall N = 422 | |
|---|---|---|---|---|---|
| Age at last visit, years a | 35 (30–42)b | 32 (29–40) | 34 (29–40) | 36 (32–42) | 35 (29–41) |
| Male sex a | 62% | 68% | 78% | 51% | 65% |
| ART in use at last visit | 82% | 77% | 47% | 58% | 73% |
| CD4+ T-cells /mm 3 at last visit c | 126 (39–287) | 183 (110–317) | 231 (141–387) | 259 (177–308) | 159 (60–312) |
| CD4+ T-cells /mm 3 at last visit c , category | |||||
| 0–50 | 28% | 17% | 6.7% | 7.7% | 22% |
| 51–100 | 15% | 4.4% | 6.7% | 7.7% | 12% |
| 101–200 | 23% | 30% | 27% | 23% | 24% |
| 201–350 | 18% | 30% | 33% | 46% | 24% |
| 351–500 | 9.4% | 13% | 20% | 0% | 10% |
| > 500 | 7.3% | 4.4% | 6.7% | 15% | 7.5% |
| Duration since KS diagnosis at last visit, months | 0.96 (0–3.5) | 1.9 (0.3–4.7) | 1.9 (0–8.3) | 4.7 (0.6–18.1) | 1.4 (0.03–5.1) |
| Duration of being lost at database closure, months | 17 (11–22) | 30 (19–39) | 31 (17–47) | 26 (14–46) | 21 (13–30) |
ART denotes antiretroviral therapy; AMPATH denotes Academic Model Providing Access to Healthcare; ISS denotes Immune Suppression Syndrome; UATH denotes University of Abuja Teaching Hospital; and NHA denotes National Hospital of Abuja
a Age missing for 1 person in AMPATH and 1 person in UATH/NHA; sex is missing for 1 person in UATH/NHA
b median (Interquartile range) unless otherwise noted
c 65% missing CD4 count overall (59% AMPATH, 71% ISS, 80% Lighthouse, and 64% UATH/NHA)